---
title: "Brainstorm Cell | 8-K: FY2025 Q1 EPS Beats Estimate at USD -0.45"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/240453750.md"
datetime: "2025-05-15T21:08:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240453750.md)
  - [en](https://longbridge.com/en/news/240453750.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240453750.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/240453750.md) | [English](https://longbridge.com/en/news/240453750.md)


# Brainstorm Cell | 8-K: FY2025 Q1 EPS Beats Estimate at USD -0.45

EPS: As of FY2025 Q1, the actual value is USD -0.45, beating the estimate of USD -0.97.

### Cash and Cash Equivalents

Cash, cash equivalents, and restricted cash were approximately $1.8 million as of March 31, 2025.

### Research and Development Expenditures

Research and development expenditures, net, for the quarter ended March 31, 2025, were $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024.

### General and Administrative Expenses

General and administrative expenses for the quarter ended March 31, 2025, were approximately $1.8 million, compared to approximately $1.5 million for the quarter ended March 31, 2024.

### Net Loss

Net loss for the quarter ended March 31, 2025, was approximately $2.9 million, as compared to a net loss of approximately $3.4 million for the quarter ended March 31, 2024. Net loss per share for the three months ended March 31, 2025, and 2024 was $0.45 and $0.75, respectively.

### Outlook / Guidance

BrainStorm Cell Therapeutics is focused on advancing its NurOwn® development program, with plans to initiate a Phase 3b trial to confirm the product’s efficacy in early-stage ALS patients and support a new BLA submission. The company has submitted an IND amendment to the FDA and is finalizing clinical trial agreements with leading academic centers. BrainStorm believes that NurOwn, if approved, has the potential to become a valuable treatment option for ALS patients.

### 相關股票

- [Brainstorm Cell (BCLI.US)](https://longbridge.com/zh-HK/quote/BCLI.US.md)

## 相關資訊與研究

- [Brainstorm Cell Therapeutics 2025 10-K: $0.0M Revenue, $(1.11) EPS](https://longbridge.com/zh-HK/news/281252153.md)
- [Brainstorm Cell Therapeutics Arranges Up to $1.0 Million Private Placement at $0.60, Adds Warrants](https://longbridge.com/zh-HK/news/277251891.md)
- [What's Behind The Jump In Virax Biolabs Stock?](https://longbridge.com/zh-HK/news/281208387.md)
- [BUZZ-NewcelX rises after raising funds at premium to boost diabetes program](https://longbridge.com/zh-HK/news/281358909.md)
- [20:49 ETThe $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step](https://longbridge.com/zh-HK/news/281274877.md)